Oregon Health and Science University, Portland, OR, USA.
OCHIN Inc., Portland, OR, USA.
J Gen Intern Med. 2023 Oct;38(13):2970-2979. doi: 10.1007/s11606-023-08139-x. Epub 2023 Mar 28.
It is uncertain if the American College of Cardiology/American Heart Association (ACC/AHA) 2013 guidelines for the use of HMGCoA reductase inhibitors (statins) were associated with increased statin eligibility and prescribing across underserved groups.
To analyze, by race, ethnicity, and preferred language, patients with indications for and presence of a statin prescription before and after the guideline change.
Retrospective cohort study.
Multistate community health center (CHC) network with linked electronic health records.
Low-income patients aged ≥ 50 with a primary care visit in 2009-2013 or 2014-2018.
(1) Odds of each race/ethnicity/language group meeting statin eligibility via the National Cholesterol Education Program Adult Treatment Panel III Guidelines in 2009-2013 or the ACC/AHA guidelines in 2014-2018. (2) Among those eligible, odds of each group in each period with a statin prescription.
In 2009-2013 (n = 109,330), non-English-preferring Latino (OR = 1.10, 95% CI = 1.03, 1.17), White (OR = 1.41, 95% CI = 1.16, 1.72), and Black patients (OR = 1.25, 95% CI = 1.11, 1.42), were more likely than English-preferring non-Hispanic Whites to meet guideline criteria for statins. Non-English-preferring Black patients, when eligible, were no more likely than non-Hispanic Whites to have statin prescriptions (OR = 1.16, 95% CI = 0.88, 1.54). In 2014-2018 (n = 319,904), English-preferring Latino patients (OR = 1.02, 95% CI = 0.96-1.07) and non-English-preferring Black patients (OR = 1.08, 95% CI = 0.98, 1.19) had similar odds of statin prescription to English-preferring non-Hispanic White patients. English-preferring Black patients were less likely (OR = 0.95, 95% CI = 0.91-0.99) to have a prescription than English-preferring non-Hispanic Whites.
Across the 2013 ACC/AHA guideline change in CHCs serving low-income patients, non-English-preferring patients were consistently more likely to be eligible for and have been prescribed statins. English-preferring Latino and English-preferring Black patients experienced reduced prescribing, comparatively, after the guideline change. Further work should explore the contextual factors that may influence guideline effectiveness and care equity.
尚不确定美国心脏病学会/美国心脏协会(ACC/AHA)2013 年关于使用羟甲基戊二酰辅酶 A 还原酶抑制剂(他汀类药物)的指南是否会增加服务不足人群中他汀类药物的适用性和处方数量。
通过种族、族裔和首选语言分析指南改变前后有他汀类药物适应证和有他汀类药物处方的患者。
回顾性队列研究。
具有电子病历的多州社区卫生中心(CHC)网络。
2009-2013 年或 2014-2018 年期间在初级保健就诊的≥50 岁低收入患者。
(1)2009-2013 年(NCEP ATP III 指南)和 2014-2018 年(ACC/AHA 指南),每个种族/族裔/语言组符合他汀类药物适应证的可能性。(2)在符合条件的患者中,每个时期每个组开具他汀类药物处方的可能性。
在 2009-2013 年(n=109330)中,与首选英语的非西班牙裔白人相比,非英语首选的拉丁裔(OR=1.10,95%CI=1.03,1.17)、白种人(OR=1.41,95%CI=1.16,1.72)和黑种人(OR=1.25,95%CI=1.11,1.42)更有可能符合他汀类药物的指南标准。非英语首选的黑人患者,如果符合条件,开具他汀类药物处方的可能性与非西班牙裔白人患者一样低(OR=1.16,95%CI=0.88,1.54)。在 2014-2018 年(n=319904)中,首选英语的拉丁裔患者(OR=1.02,95%CI=0.96-1.07)和非英语首选的黑人患者(OR=1.08,95%CI=0.98,1.19)与首选英语的非西班牙裔白人患者相比,开具他汀类药物处方的可能性相似。首选英语的黑人患者开具他汀类药物处方的可能性较低(OR=0.95,95%CI=0.91-0.99)。
在为低收入患者服务的 CHC 中,2013 年 ACC/AHA 指南改变后,非英语首选的患者一直更有可能符合他汀类药物的适应证并开具了他汀类药物处方。与指南改变前相比,首选英语的拉丁裔和首选英语的黑人患者开具他汀类药物处方的比例相对较低。进一步的研究应探讨可能影响指南效果和医疗公平性的背景因素。